RecruitingNCT07040774

Natural History of Type 1 Interferonopathies: Insights From a European Cohort


Sponsor

Imagine Institute

Enrollment

500 participants

Start Date

Oct 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Type I interferonopathies are rare autoinflammatory disorders caused by genetic defects and associated with significant morbidity and mortality. These diseases are refractory to conventional immunosuppressive therapies. They typically occur in childhood, although disease onset in adulthood has been observed. The clinical spectrum is wide and mainly involves the central nervous system. Joint involvement is also common, and more rarely, haematological features such as cytopenias or immunodeficiency may be observed. Nearly all patients show consistent over-activation of the type I IFN pathway, as evidenced, the expression of IFN-stimulated genes, the so-called 'interferon signature'. To date, the natural history of interferonopathies remains unclear. In this context, the establishment of a natural history of type I interferonopathy in patients is proposed to elucidate the pathophysiological mechanisms and identify biomarkers for diagnosis, prognosis, and disease activity, with the aim of better characterising the diversity of interferonopathies. The main objective is to characterise the evolution of the pathology in paediatric and adult patients with type I interferonopathies. The overall aim of this research is to propose therapeutic options tailored to patient phenotypes and to better define patient sub-groups in order to optimise the preparation of future clinical trials.


Eligibility

Inclusion Criteria2

  • Genetically confirmed patient with type I interferonopathy
  • Patient affiliated to a social security scheme or beneficiary of such a scheme.

Exclusion Criteria1

  • \- Opposition of the patient and/or parental authority if the patient is a minor, to participation in the study.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(32)

Medical University Innsbruck

Innsbruck, Austria

Antwerp University Hospital

Antwerp, Belgium

Children's Hospital Zagreb

Zagreb, Croatia

Motol University Hospital

Prague, Czechia

CHU d'Angers

Angers, France

Hôpital de Mercy - CHR Metz Thionville

Ars-Laquenexy, France

CHU de Besançon

Besançon, France

CHU de Bordeaux

Bordeaux, France

CHU Morvan

Brest, France

Hôpital Femme Mère Enfant - HCL

Bron, France

CHU de Dijon

Dijon, France

Hôpitaux Nord Ouest Villefranche

Gleizé, France

Hôpital Bicêtre

Le Kremlin-Bicêtre, France

Hôpital Claude Huriez, CHU de Lille

Lille, France

APHM Hôpitaux de Marseille

Marseille, France

CHU de Montpellier

Montpellier, France

CHRU Nancy

Nancy, France

CHU de Nantes

Nantes, France

CH Agen-Nérac

Nérac, France

Hôpital de l'Archet

Nice, France

Hôpital Armand Trousseau

Paris, France

Hôpital Bichat

Paris, France

Hôpital Robert Debré

Paris, France

Hôpital des Enfants - CHU de Toulouse

Toulouse, France

Hôpital Necker Enfants Malades

Paris, Île-de-France Region, France

University of Tübingen

Tübingen, Germany

Meyer Children's Hospital IRCCS

Florence, Italy

Hospital Universitari Vall d'Hebron

Barcelona, Spain

Hospital Universitario Son Espases

Palma de Mallorca, Spain

Karolinska University Hospital

Stockholm, Sweden

Hacettepe İhsan Doğramacı Children's Hospital

Ankara, Turkey (Türkiye)

Leeds Teaching Hospitals NHS Trust

Leeds, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07040774


Related Trials